Publication | Open Access
Safety and efficacy of nusinersen in spinal muscular atrophy: The <scp>EMBRACE</scp> study
107
Citations
21
References
2021
Year
Nusinersen demonstrated a favorable long-term benefit-risk profile in this broad population of individuals with infantile- or later-onset SMA.
| Year | Citations | |
|---|---|---|
Page 1
Page 1